Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers

Journal of Cancer Research and Clinical Oncology
Maurie MarkmanJerome Belinson

Abstract

There are limited data available in the oncology literature regarding the risk of thrombocytopenia associated with carboplatin-based second-line treatment of ovarian cancer, outside the setting of patients participating in clinical trials. To examine this clinically-relevant issue, we conducted a retrospective review of the medical records of women with ovarian cancer treated in the Gynecologic Cancer Program of the Cleveland Clinic from 1994 through November 2003, who received >2 second-line carboplatin-based regimens. A total of 176 second-line carboplatin-based programs were delivered to the 152 patients (median age 61 years; range 39-87 years) identified through this review. A total of ten (7%) patients experienced >grade 2 thrombocytopenia, with only four (3%) patients developing platelet count nadirs <50.0 x 10(9)/l. No patient required discontinuation of platinum-based therapy due to the development of thrombocytopenia. Second-line carboplatin-based chemotherapy of ovarian cancer is associated with a low incidence of serious thrombocytopenia, if a strategy of selecting modest initial dose levels, and instituting rapid reductions in dose with the development of significant bone marrow suppression, is employed.

References

Apr 1, 1992·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·D I JodrellE Wiltshaw
Jul 1, 1995·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·W P McGuireJ Woodward
Nov 1, 1994·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·G L GoldbergE R Burns
Jan 1, 1997·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A JakobsenI Stroeyer
Apr 29, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P G RoseM Rodriguez
Jul 17, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M GoreJ Shepherd
Mar 8, 2000·The Oncologist·M Markman, M A Bookman
Mar 30, 2001·Gynecologic Oncology·G BolisUNKNOWN Associazione per la Ricerca in Ginecologia Oncologia (ARGO 96) Study Group
Mar 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Don S DizonDavid R Spriggs
Jul 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert F OzolsUNKNOWN Gynecologic Oncology Group

❮ Previous
Next ❯

Citations

Mar 26, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Andrew BerchuckJohnathan M Lancaster
Feb 4, 2014·Nanomedicine : Nanotechnology, Biology, and Medicine·Jian LiGiorgia Pastorin
Jun 25, 2005·Clinical Journal of Oncology Nursing·Kathleen Bonosky, Rickey Miller

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.